The ABL kinase inhibitor STI571 does not affect survival of hematopoietic cells after ionizing radiation

被引：0
|
作者：
Uemura, N [1 ]
Griffin, JD [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
BLOOD | 2000年 / 96卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3294 / 3295
页数：2
相关论文
共 50 条
  • [31] BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571
    Donato, NJ
    Wu, JY
    Stapley, J
    Gallick, G
    Lin, H
    Arlinghaus, R
    Talpaz, M
    BLOOD, 2003, 101 (02) : 690 - 698
  • [32] Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro
    Mow, BMF
    Chandra, J
    Svingen, PA
    Hallgren, CG
    Weisberg, E
    Kottke, TJ
    Narayanan, VL
    Litzow, MR
    Griffin, JD
    Sausville, EA
    Tefferi, A
    Kaufmann, SH
    BLOOD, 2002, 99 (02) : 664 - 671
  • [33] The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy
    Attoub, S
    Rivat, C
    Rodrigues, S
    Van Bocxlaer, S
    Bedin, M
    Bruyneel, E
    Louvet, C
    Kornprobst, M
    André, T
    Mareel, M
    Mester, J
    Gespach, C
    CANCER RESEARCH, 2002, 62 (17) : 4879 - 4883
  • [34] Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells
    Kawauchi, K
    Ogasawara, T
    Yasuyama, M
    Ohkawa, S
    BLOOD CELLS MOLECULES AND DISEASES, 2003, 31 (01) : 11 - 17
  • [35] Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL-expressing cells, demonstrating synergy between AG490 and STI571
    Sun, XM
    Layton, JE
    Elefanty, A
    Lieschke, GJ
    BLOOD, 2001, 97 (07) : 2008 - 2015
  • [36] Modification of the clonogenic capacity of bone marrow cells from normal individuals by the tyrosine kinase inhibitor STI571
    Prejzner, W
    Knopinska-Posluszny, W
    Mikolajczuk, J
    Langowska, B
    Hellmann, A
    CLINICAL AND LABORATORY HAEMATOLOGY, 2003, 25 (05): : 293 - 296
  • [37] Structure-activity studies supporting a postulated binding mode of STI571 to Abl kinase.
    Fabbro, D
    Furet, P
    Buchdunger, E
    Loiseleur, O
    Meyer, T
    Zimmermann, J
    Manley, PW
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3772S - 3773S
  • [38] The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR–ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents
    W M Liu
    L A Stimson
    S P Joel
    British Journal of Cancer, 2002, 86 : 1472 - 1478
  • [39] DNA damage and repair in BCR/ABL-expressing cells after combined action of idarubicin, STI571 and amifostine
    Blasiak, J
    Gloc, E
    Pertynski, T
    Drzewoski, J
    ANTI-CANCER DRUGS, 2002, 13 (10) : 1055 - 1060
  • [40] STI571: A tyrosine kinase inhibitor for the treatment of CML - Validating the promise of molecularly targeted therapy
    Druker, BJ
    FASEB JOURNAL, 2002, 16 (04): : A134 - A134
12345